Clinical trial · Interventional
[18F]BF3-BPA Injection for PET Imaging Study of Gliomas in the Brain
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this clinical study, we proposed to perform \[18F\]BF3-BPA PET imaging in subjects with gliomas, to observe the binding ability and non-specific binding of the tracer to glioma lesions in vivo, and at the same time to evaluate the effectiveness of \[18F\]BF3-BPA in the diagnosis and differential diagnosis of glioma, and to evaluate the tolerability and safety of the tracer and the imaging method. The efficacy of \[18F\]BF3-BPA in the diagnosis and differential diagnosis of gliomas will be evaluated, as well as the tolerability and safety of this tracer and imaging method. This study will provide a new method for in vivo imaging of gliomas and provide a clear and intuitive imaging basis for clinical diagnosis, differential diagnosis and treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cerebral Gliosis | — | UNRESOLVED | — |
| Positron Emission Tomography | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]BF3-BPA Injection for PET Imaging | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Low-dose group
- description
- Subjects in this group were injected intravenously with 5 ± 1 mCi \[18F\]BF3-BPA
- interventionNames
- Radiation: [18F]BF3-BPA Injection for PET Imaging
- type
- EXPERIMENTAL
- label
- High-dose group
- description
- Subjects in this group were injected intravenously with 9 ± 1 mCi \[18F\]BF3-BPA
- interventionNames
- Radiation: [18F]BF3-BPA Injection for PET Imaging
Primary outcomes (1)
- measure
- Complete PET imaging
- timeFrame
- 90mins from time of injection
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Patients with suspicious brain gliomas: * Patients diagnosed by the investigator, based on symptoms, course of disease, and MRI of the head, as having a suspected high- or low-grade brain glioma, scheduled for brain tumor resection, and with no contraindications to surgery; * No prior and/or current surgery, radiotherapy, or puncture biopsy (other than treatment for symptomatic relief) for brain tumors; * No other primary malignant tumor. 2. age ≥ 18 years; 3. Eastern Cooperative Oncology Group (ECOG) 0-2; 4. adequate organ function: * Platelet count \>100 x 109/L; * Urea/urea nitrogen and serum creatinine \<1.5 times upper limit of normal (ULN); * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times ULN. 5\. Subjects should be fully informed of the content, process and possible risks of the test and voluntarily sign an informed consent form. Exclusion Criteria: * Subjects meeting any of the following criteria will be excluded from the study: 1. Severe allergic reaction to any of the drugs or their components in this trial; 2. Those who cannot tolerate or are contraindicated to undergo MRI and PET; 3. Those who cannot accept or tolerate blood sample collection; 4. Those who are unable to use effective contraception from the date of signing the informed consent to 3 months after the administration of the drug; 5. pregnant or lactating women or those with positive blood pregnancy test results; 6. Those who have participated in other interventional clinical trials prior to the date of informed consent and are within 5 half-lives of the trial drug, or are participating in other interventional clinical trials;
References
Publications (0)
Data not yet available